Posters on the topic "CGRP (receptor) inhibitors in the clinic"

Back
  • P001
  • ePoster
Constipation as an adverse effect of all the subcutaneous anti CGRP monoclonal antibodies: relation to pre-existing constipation and impact on migraine treatment
  • Teresa Ascensão Pinheiro (Amadora, PT)
  • P002
  • ePoster
Calcitonin gene-related peptide monoclonal antibodies and concomitant autoimmune related disorders
  • P003
  • ePoster
Blood pressure in migraine patients undergoing treatment with CGRP monoclonal antibodies in patients with migraine – a systematic review and potential implications for clinical practice
  • P004
  • ePoster
Anti-CGRP monoclonal antibodies treatment discontinuation in migraine: when and why
  • P005
  • ePoster
Efficacy and safety of rimegepant for the preventive treatment of fasting-related headache during Ramadan in the UAE
  • P006
  • ePoster
Efficacy and safety of rimegepant for the acute treatment of migraine in Japan
  • P007
  • ePoster
Efficacy and safety of rimegepant for the prevention of migraine in Japan
  • P008
  • ePoster
Consistency of effect of rimegepant as an acute treatment for migraine attacks: Data from a real-world survey
  • P009
  • ePoster
Cognitive improvement in a patient undergoing Eptinezumab for the treatment of chronic migraine – a case report
  • P010
  • ePoster
Real-world effectivenes and tolerability of switching between CGRP pathway tageting antibodies: Czech Migraine Registry (ReMig)
  • P011
  • ePoster
Fremanezumab for the treatment of migraine and medication overuse headache – a systematic review and meta-analysis
  • P012
  • ePoster
Effectiveness and safety of anti-CGRP treatment in migraine patients with autoimmune diseases: multicenter "ImmunoCGRP" case-control study
  • P092
  • ePoster
Eptinezumab treatment in patients with previous anti-CGRP(R) monoclonal antibodies therapy (mAbs) – a retrospective study of real-world clinical evidence of efficacy
  • P093
  • ePoster
Effectiveness and tolerability of lasmiditan in the acute migraine treatment (DART) – a real-world multicentric study
  • P094
  • ePoster
Evaluating safety, effectiveness, and impact on multiple sclerosis disease course of Anti-CGRP monoclonal antibodies combined with disease-modifying treatments – a multicentric study
  • P095
  • ePoster
A multidisciplinary multicentric approach to the identification of BIOmarkers of MIGraine (BIOMIGA project): an open-label, prospective biochemical study based on the stratification of responders to Erenumab
  • P096
  • ePoster
Effectiveness and tolerability of fremanezumab in real-world clinical practice:Results of the 24-month prospective observational study FINESSE
  • P097
  • ePoster
Real-world long-term effectiveness of fremanezumab in patients with migraine who switched from another mAb targeting the CGRP pathway – subgroup analysis of the FINESSE full analysis
  • P098
  • ePoster
Lessons with fremanezumab as the third CGRP antibody in our hospital: focus on factors predicting response
  • P099
  • ePoster
Restarting migraine preventive treatment with CGRP antibodies after drug holiday: Insights from Pavia real-world experience
  • P100
  • ePoster
Clinical impact of Rimegepant in acute migraine management for triptan non-responders
  • P101
  • ePoster
Switching anti-CGRP monoclonal antibodies benefits 25% of non-responders – an observational study of 82 cases
  • P102
  • ePoster
Evaluating the efficacy of monoclonal antibodies targeting CGRP in migraine treatment and the effect of combination therapy with Onabotulinum Toxin Type-A – a retrospective study
  • P103
  • ePoster
Characteristics of people with migraine using rimegepant in the Adelphi migraine Disease Specific ProgrammeTM (DSP)
  • P250
  • ePoster
Real-life experience of rimegepant in episodic migraine
  • P251
  • ePoster
Anti-CGRP antibodies in patients with migraine and autoimmune disease with concomitant immunosuppressants/immunomodulators treatment: interactions, safety and effectiveness
  • P252
  • ePoster
Response to eptinezumab in chronic cluster headache – a case report
  • P253
  • ePoster
Characteristics of patients prescribed rimegepant vs. all patients seeking migraine care via telemedicine
  • P254
  • ePoster
Is Erenumab effective and safe in long term migraine treatment? A three-years observational study
  • P255
  • ePoster
A 3-year migraine management with anti-CGRP monoclonal antibodies: an intention-to-treat analysis of real-world evidence
  • P256
  • ePoster
The effect of 9-months fremanezumab preventive treatment on the triptan response and on the incidence of triggers and prodromal symptoms in patients with HFEM
  • P257
  • ePoster
Multi-parametric efficacy assessment of Eptinezumab in patients with chronic migraine and medication overuse headache – early results from a third level headache center
  • P258
  • ePoster
Quarterly fremanezumab: assessing migraine relief and patient satisfaction
  • P259
  • ePoster
Refractory chronic migraine: no symptomatic relief after 20 preventive medications
    • v1.20.0
    • © Conventus Congressmanagement & Marketing GmbH